130
Views
0
CrossRef citations to date
0
Altmetric
Menopause

Bazedoxifene plus conjugated estrogens improve menopausal symptoms in postmenopausal women: a systematic review and meta-analysis

, , &
Pages 813-821 | Received 09 Jun 2022, Accepted 22 Aug 2022, Published online: 28 Aug 2022

References

  • Noll PRESCampos CAS, Leone C, Zangirolami-Raimundo J, et al. Dietary intake and menopausal symptoms in postmenopausal women: a systematic review. Climacteric. 2021;24(2):128–138.
  • Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497–515.
  • Santoro N, Roeca C, Peters BA, et al. The menopause transition: Signs, symptoms, and management options. J Clin Endocrinol Metab. 2021;106(1):1–15.
  • Zhang L, Ruan X, Cui Y, et al. Menopausal symptoms among Chinese peri- and postmenopausal women: a large prospective single-center cohort study. Gynecol Endocrinol. 2021;37(2):185–189.
  • Pinkerton JV, Bushmakin AG, Komm BS, et al. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning. Maturitas. 2017;100:57–63.
  • Monteleone P, Mascagni G, Giannini A, et al. Symptoms of menopause - global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199–215.
  • Wang YP, Yu Q. The treatment of menopausal symptoms by traditional Chinese medicine in Asian countries. Climacteric. 2021;24(1):64–67.
  • Stuenkel CA. Managing menopausal vasomotor symptoms in older women. Maturitas. 2021;143:36–40.
  • Rozenberg S, Vandromme J, Antoine C. Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol. 2013;9(4):216–227.
  • Çilgin H. Predictors of initiating hormone replacement therapy in postmenopausal women: a cross-sectional study. Sci World J. 2019;2019:1–8.
  • Yavropoulou MP, Makras P, Anastasilakis AD. Bazedoxifene for the treatment of osteoporosis. Expert Opin Pharmacother. 2019;20(10):1201–1210.
  • Zimmerman MA, Hutson DD, Mauvais-Jarvis F, et al. Bazedoxifene-induced vasodilation and inhibition of vasoconstriction is significantly greater than estradiol. Menopause. 2019;26(2):172–181.
  • Pinkerton JV, Conner EA. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric. 2019;22(2):140–147.
  • Kim BM, Kim SE, Lee D-Y, et al. Effect of tissue-selective estrogen complex on hip structural geometry in postmenopausal women: a 12-month study. Front. Endocrinol. 2021;12:649952.
  • Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92(3):1039–1044.
  • Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013;121(5):959–968.
  • Pinkerton JV, Bushmakin AG, Bobula J, et al. Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies. Menopause. 2017;24(12):1378–1385.
  • Pinkerton JV, Abraham L, Bushmakin AG, et al. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the selective estrogens, menopause and response to therapy (SMART) trials. J Womens Health (Larchmt). 2014;23(1):18–28.
  • Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16(6):1116–1124.
  • Palacios S, Arias L, Lavenberg J, et al. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a latin American population. Climacteric. 2016;19(3):261–267.
  • Archer DF, Freeman EW, Komm BS, et al. Pooled analysis of the effects of conjugated estrogens/bazedoxifene on vasomotor symptoms in the selective estrogens, menopause, and response to therapy trials. J Womens Health (Larchmt). 2016;25(11):1102–1111.
  • Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132–140.
  • Hadji P, Ryan KA, Yu CR, et al. CE/BZA effects on bone and quality of life in european postmenopausal women: a pooled analysis. Climacteric. 2016;19(5):482–487.
  • Pinkerton JV, Pan K, Abraham L, et al. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Menopause. 2014;21(3):252–259.
  • Pinkerton JV, Pickar JH, Ryan KA, et al. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials. Menopause. 2016;23(6):611–620.
  • Utian W, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009;63(4):329–335.
  • Zhang G-Q, Chen J-L, Luo Y, et al. Menopausal hormone therapy and women’s health: an umbrella review. PLoS Med. 2021;18(8):e1003731.
  • Brennan A, Rees M. Menopausal hormone therapy in women with benign gynaecological conditions and cancer. Best Pract Res Clin Endocrinol Metabol. 2021;35(6):101575.
  • Pickar JH, Lavenberg J, Pan K, et al. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study. Menopause. 2018;25(3):273–285.
  • Gallagher JC, Palacios S, Ryan KA, et al. Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. Menopause. 2016;23(10):1083–1091.
  • Komm BS, Thompson JR, Mirkin S. Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials. Climacteric. 2015;18(4):503–511.
  • Mallhi TH, Khan YH, Khan AH, et al. Managing hot flushes in menopausal women: a review. J Coll Physicians Surg Pak. 2018;28(6):460–465.
  • Stuenkel CA. Menopausal hormone therapy and the role of estrogen. Clin Obstet Gynecol. 2021;64(4):757–771.
  • Chen M-n, Lin C-C, Liu C-f Efficacy of phytoestrogens for menopausal symptoms: a Meta-analysis and systematic review. Climacteric. 2015;18(2):260–269.
  • Pinkerton JV, Bushmakin AG, Abraham L, et al. Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene. Menopause. 2017;24(9):1011–1016.
  • Ahmadieh H, Jradi N. Prevalence of menopausal hot flashes in Lebanon: a cross-sectional study. Int J Reprod Biomed. 2021;19(9):789–800.
  • De Franciscis P, Guida M, Schiattarella A, et al. Safety of non-hormonal medications for managing hot flashes. Expert Opin Drug Saf. 2022;21(2):215–221.
  • Palacios S. Assessing symptomatic vulvar, vaginal, and lower urinary tract atrophy. Climacteric. 2019;22(4):348–351.
  • Cintron D, Lipford M, Larrea-Mantilla L, et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and Meta-analysis. Endocrine. 2017;55(3):702–711.
  • Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis of randomized controlled trial data. J Clin Endocrinol Metab. 2021;106(4):942–951.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.